These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9635908)

  • 1. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
    Zhanel GG; Karlowsky JA; Hoban DJ
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
    Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
    Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
    Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
    Hardy D; Amsterdam D; Mandell LA; Rotstein C
    Antimicrob Agents Chemother; 2000 Mar; 44(3):802-5. PubMed ID: 10681365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
    Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
    Heinemann B; Wisplinghoff H; Edmond M; Seifert H
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
    Clark CL; Nagai K; Davies TA; Bozdogan B; Dewasse B; Jacobs MR; Appelbaum PC
    Clin Microbiol Infect; 2002 Jun; 8(6):373-80. PubMed ID: 12084107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci.
    Perri MB; Chow JW; Zervos MJ
    Diagn Microbiol Infect Dis; 1993; 17(2):151-5. PubMed ID: 8243036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
    Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
    Hoppe JE; Dalhoff A; Pfründer D
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1868. PubMed ID: 9661039
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM; Singh KV; Murray BE
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):369-70. PubMed ID: 8192468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
    Schick DG; Canawati HN; Montgomerie JZ
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species.
    Hayden MK; Matushek MG; Trenholme GM
    Diagn Microbiol Infect Dis; 1995 Aug; 22(4):349-52. PubMed ID: 8582142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.
    Sánchez-Silos RM; Pérez-Giraldo C; Blanco MT; Morán FJ; Hurtado C; Gómez-García AC
    Chemotherapy; 2001 Dec; 47(6):415-20. PubMed ID: 11786656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
    Johnson AP; Warner M; Livermore DM
    Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.